No Data
No Data
Cautious Optimism: Q32 Bio's Strategic Shift to Focus on Bempikibart for Alopecia Areata
Analysts Offer Insights on Healthcare Companies: Voyager Therapeutics (VYGR), Q32 Bio (QTTB) and Vaxcyte (PCVX)
Q32 Downgraded to Market Perform by BMO Over ADX-097
BMO Capital Downgrades Q32 Bio(QTTB.US) to Hold Rating, Cuts Target Price to $3
Q32 Bio Unveils Restructuring to Focus on Alopecia Areata Treatment; Shares Fall
Q32 Cut to Neutral by Piper on ADX-097 Discontinuation
Unlock the Full List